Pharma

Your Article Summary

See Latest Articles

FDA grants marketing approval for Lundbeck's Sabril (vigabatrin)
Lundbeck, 08/24/09

H. Lundbeck A/S announced that the US Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril Tablets and Oral Solution. Lundbeck Inc. plans to launch Sabril in the US during the third quarter of 2009, with an extensive Risk Evaluation and Mitigation Strategy (REMS) program as required by the FDA and created in collaboration with the agency.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

 See all of Drug Trials